The blood-brain barrier (BBB) plays a crucial role in maintaining brain homeostasis and transport of drugs to the brain. The conventional animal and Transwell BBB models along with emerging microfluidic-based BBB-on-chip systems have provided fundamental functionalities of the BBB and facilitated the testing of drug delivery to the brain tissue. However, developing biomimetic and predictive BBB models capable of reasonably mimicking essential characteristics of the BBB functions is still a challenge. In addition, detailed analysis of the dynamics of drug delivery to the healthy or diseased brain requires not only biomimetic BBB tissue models but also new systems capable of monitoring the BBB microenvironment and dynamics of barrier function and delivery mechanisms. This review provides a comprehensive overview of recent advances in microengineering of BBB models with different functional complexity and mimicking capability of healthy and diseased states. It also discusses new technologies that can make the next generation of biomimetic human BBBs containing integrated biosensors for real-time monitoring the tissue microenvironment and barrier function and correlating it with the dynamics of drug delivery. Such integrated system addresses important brain drug delivery questions related to the treatment of brain diseases. We further discuss how the combination of in vitro BBB systems, computational models and nanotechnology supports for characterization of the dynamics of drug delivery to the brain.
Introduction
The cross-talk between the brain and the periphery occurs via flow and diffusional processes through different central nervous system (CNS) barriers at the cerebral microvascular endothelium, choroid plexus epithelium, and avascular arachnoid epithelium [1] [2] [3] . These barriers contribute to bioavailability of drugs and translocation of endobiotics and immune cells. Among CNS barriers, the cerebral microvascular endothelium forms the largest barrier in the brain and functions as an effective brain barrier, so called "blood-brain barrier" (BBB). The BBB along with blood-cerebrospinal fluid (CSF) barrier control the passage of a variety of molecules and contribute to maintaining the homeostasis of the ions and cells between the blood and neural tissues [1] [2] [3] . The BBB stringently regulates the extracellular environment of neural tissues and protects the CNS from the passage of blood-borne toxins, proteins and cells restricting the access of different cells and molecules to the brain tissue [4] [5] [6] . External forces like microgravity can also interrupt endothelial cells (ECs) and may lead to the BBB dysfunction [7] . The breakdown of BBB results in detrimental neurological disorders and might lead to neurodegeneration. On the other hand, cerebral microvascular endothelium restricts the drug uptake limiting the appropriate treatments of neurological disorders. The development of physiologically relevant models of BBB supports the recognition of cellular and molecular mechanisms regulating the BBB functions and provides valuable insights for the design of appropriate drugs with efficient delivery to the brain.
In this review, we discuss the BBB functions and signaling pathways for drug transport, and the performance of in vivo animal BBB models and a variety of different in vitro BBB models. We further explain modern technologies used to generate biomimetic human BBB models, and finally discuss BBB-on-chip models with integrated monitoring systems for drug discovery application. The complementary role of computational models and nanotechnology is further discussed along with the experimental setups for controlling the transport mechanism of medicines and enhancing the permeability and stability of drugs and nano-formulations. The future predictive BBB models need to consider the advantages of new technologies like microtechnology-based biomimetic human BBB models, integrated biosensors, computational analysis and nanomedicine for systematic analysis of the transport and stability of neuro-pharmaceuticals across the healthy or diseased BBB in order to provide a reliable tool complementing animal and human studies.
Blood-brain barrier
The capillary bed of CNS vasculature is mainly formed by endothelial cells (ECs) and maintained by pericytes around the capillaries while astrocytes end-feet surrounding these two layers. The association of neuronal cells with vascular cells and extracellular matrix components (like collagens, laminins and heparin sulfate proteoglycans) is called neurovascular unit. Tight junctions (TJs) hold ECs together constitute the most apical intracellular complex [8] . However, given the complexity of the CNS vasculature, there is a vast heterogeneity in the function and signaling pathways of transport for distinct regions of the BBB in the CNS.
Heterogeneity and functions of BBB
Several different proteins and cells take participate in BBB formation and functioning. TJs in the BBB are internal membrane proteins and interact with cytoplasmic scaffolding proteins including zonula occludins (ZO), actin cytoskeleton and other associated proteins comprising the protein kinases, small GTPases, and heterotrimeric G-proteins [8, 9] . Claudins, as the most important TJs, consist of PMP22/ EMP/MP20/claudin family characterized by a W-GLW-C-C domain in their first external loop [10] . More than 20 claudins have been reported in mammals in which different barriers are composed of distinctive claudin family members [11] . Claudin type in TJs is suggested as the key element of the barrier permeability. For instance, claudin 5 (the most abundant claudin in endothelium) deficient mice have a leaky BBB to small molecules and die at the birth [12] . However, the exact role of some claudins such as claudin 3 and claudin 12 in BBB formation and consistency is not clear yet [12, 13] . Cytoplasmic TJ proteins like ZO-1, ZO-2, ZO-3, Jacop, MUPP1, MAGI, and cingulin bind to TJs and link them to the cytoskeleton, adherent junctions and other polar complexes [14] . ZO proteins, especially ZO-1 and ZO-2, are reported to be vital for TJ formation via binding to claudin and occludin proteins through their PDZ domain [4] . Additionally, TJs connect to basal adherent junctions, which is made of VE-cadherin and PECAM1, holding ECs together in an integrated manner [4] .
Most of the BBB junction proteins such as claudin 5, claudin 12, ZO-1, ZO-2, VE-cadherin, and PECAM1 are also found in ECs of other tissues which would suggest that the expression of these molecules is not high enough to form the BBB [13] . However, particular mechanisms that form the highly resistant TJs of the CNS are still unclear. In addition, two more proteins are present in the endothelium layer: tricellulin that forms tripartite junctions where three ECs meet, and lipolysis-simulated lipoprotein receptor (LSR) that is responsible for the localization of tricellulin proteins [15] . Recent studies revealed a higher expression of tricellulin and LSR in ECs of the BBB compared to other tissues, proposing the idea that these structures may be crucial for the BBB formation [13] .
ECs of the CNS display distinguished luminal and abluminal surfaces due to their highly polarized nature, leading to the expression of distinct transporters in the plasma membrane. These transporters are responsible for both removing potential toxins and supplying specific nutrients, and dictate the movement of various molecules and ions through the BBB [16] . ECs of the BBB express efflux transporters such as MDR1/P-glycoprotein (Pgp) and restrain the xenobiotics trafficking between blood and brain tissues. There is a wide variety of different transporters within brain ECs that sometimes shows an overlapping substrate specificity to provide a better partitioning of small molecules within the BBB [3] . In addition to efflux transporters, ECs represent a series of specific transporters which translocate particular ions, nutrients and proteins from the blood to the brain site using a range of distinct mechanisms. These transporting mechanisms can be categorized as carrier-mediated transporters (glucose and GLUT1/SLc2a1), lactate and amino acids transporters, receptor-mediated transcytosis (like transferrin receptor), and ion pumps (including Na + , K + cotransporters) [17, 18] . The recent studies have shown that different metabolic enzymes expressed in ECs of the CNS can supply particular metabolic substances to the CNS [13] . CNS cells are suggested to be the primary regulator of BBB formation and function [19] . Astrocytes reduce the permeability of the BBB to tracers and increase the trans-endothelial electrical resistance (TEER) of the BBB via expressing efflux transporters such as MDR1/Pgp in ECs [20, 21] . Astrocytes are also actively involved in the maintenance of the BBB integrity by stabilizing TJs and providing a quiescent immune environment for ECs. However, they are not required for the induction of BBB formation during embryonic development since the BBB is formed prior to astrocyte generation [22] . Furthermore, pericytes play an essential role in BBB development, maintenance, and aging through platelet-derived growth factor B signaling pathways [22] . Transcytosis of ECs and the expression of LAMs are remarkably restricted by pericytes. In addition, in vivo studies have shown that the barrier integrity of CNS is improved by transforming growth factor beta or angiopoietin 1 [23] .
From the molecular point of view, one of the most crucial signaling pathways involved in regulating the BBB is Wnt/beta-catenin signaling, particularly activated in ECs of the CNS during the development stage [13] . The inhibition of Wnt signaling during embryonic development was shown to be effective in the disruption of angiogenesis in the CNS [13] . Moreover, the expression of claudin 3 and BBB-specific transporters such as GULT1 in ECs of the CNS has been regulated by Wnt signaling pathway [24] . As a result, the BBB gene expression is at least partially regulated by signaling pathways involved in angiogenesis at the CNS. It is a major factor in the pathology of various diseases where leaky vessels are formed due to inappropriate BBB-inducing signals during the new blood vessel formation [4] . The angiogenic invasion of ECs into the CNS is suggested to induce specific gene expression of the BBB. Afterwards, astrocytes and pericytes modulate the properties of BBB during the lifetime. Understanding the molecular mechanisms behind the BBB regulation using a biomimetic BBB model can highly support the treatment of neurological and neurodegenerative disorders [24] .
There is also a functional heterogeneity in distinct regions of the BBB in the CNS. Different parts of the brain vasculature have different functions in terms of blood flow and nutrients delivery. While arterial segments show high contractile properties needed for controlling blood flow through different regions, capillaries play an important role in the delivery of nutrients and oxygen, and postcapillary venules provide a primary site for the attachment of immune cells to ECs and their infiltration through the CNS barriers [1] . A wide range of BBB genes are expressed throughout the vascular system of the CNS; however some distinct differences enriched the transport and immune properties in capillaries and venules, respectively [25] . The expression of specific transporters is also different for vessels with different diameters [13] . Furthermore, the circumventricular regions of the brain, including pineal gland, area postrema, subfornical organ, and median eminence of the hypothalamus have specializations in their BBB to support their particular functions. The vascular tree of these regions enjoys a highly permeable EC layer having partial basement membrane and lacks the pericytes coverage and astrocytes ensheathment [26] . In addition, BSCB and blood-retinal barrier display special characteristics [26] . While spinal cord has increased the permeability to cytokines and express the glycogen depositions in its vasculature, retina displays a higher coverage with pericytes than the brain. Last but not the least, the mechanisms of angiogenesis regulation seem to vary in different parts of the brain; for instance, gpr124 is only required for the angiogenesis in the forebrain but no other regions of the brain [27] .
Due to the tight regulation of various cells and molecules in the CNS, the BBB implements a sophisticated hindrance for the drug delivery to the brain. Only a narrow range of drugs can pass through the BBB [28] . Drugs can cross the BBB through different ways, including the disruption of the BBB, drug modification, and suppressing efflux transporters. Although these approaches demonstrate some advantages, there is no guarantee that the drug component ends up with the targeted cells upon passage through the BBB [4] . The drug still needs to pass through different layers, including basal membrane and astrocytes end-feet to reach their target cells (neurons or glial cells).
Molecular pathways for transportation across the BBB
Paracellular diffusion of polar solutes in cerebral endothelium is almost impossible due to the presence of TJs. Small lipophilic compounds such as acetaminophen can diffuse passively across the endothelial membrane. The lipid-mediated transport is only available for small molecules with a high lipophilicity [29, 30] . Restricting the free movement of lipid rafts and proteins enables TJs to produce the polarity of the BBB. A wide variety of transcellular transport mechanisms are responsible for the entry of ions, nutrients, and the efflux of waste products in and out of the brain. These materials are expressed either on the luminal or abluminal membrane or both membranes of the BBB [31, 32] . The major transport mechanisms for the BBB penetration include the carrier-mediated transport, active efflux transport, receptormediated transcytosis, caveolae-mediated transport and ion transport ( Fig. 1) [3] .
Carrier-mediated transporters in the BBB endothelium provide very specific nutrients to the brain. They mediate the transport of small polar molecules such as glucose, amino acids, organic anions and cations, and nucleosides. These solute carriers (SLCs) can be specific to one or several molecules [31] . The extensively expressed insulin-independent glucose transporter GLUT1 (SLC2A1) is the main carrier in the BBB that supplies glucose as the energy source for the brain [33] . Deficiency in the expression of GLUT1 protein in the BBB cells can cause a continuous shortage in energy metabolites in the brain which may lead to agingassociated cognitive decline and Alzheimer's disease (AD) [34, 35] . The concentration gradients for nutrients are generally in the direction from the blood to the brain are regulated by brain metabolic needs and concentrations of substrates in the blood. The number of GLUT1 transporters is higher at the abluminal membrane compared to the luminal membrane which provides a homeostatic control for the glucose influx into the brain [36, 37] .
Other main carrier-mediated transporters are monocarboxylate transporter1 (MCT1), amino acid transporters, adenosine transporters, and vitamin transporters [3] . MCT1 (SLC16A1) is a member of protonlinked plasma membrane transporters that mainly mediates the transport of lactate, ketone bodies, and other monocarboxylic acids cross the BBB to the brain [3] . To regulate the CNS function, thyroid hormone mostly enters the brain through the BBB by thyroid hormone transporters or MCT8 [38] . All essential amino acids such as tyrosine, leucine, threonine, and arginine are mediated by amino acid transporters [39] . These transporters can regulate the concentration of naturally occurred amino acids in the brain and are responsible for removing toxic amino acids from the brain [39, 40] . The glutamate removal as a mechanism for maintaining low extracellular concentrations of the glutamate in the brain is mediated by a sodium dependant system for excitatory acidic amino acids (EAAT, SLC1A family) [3] . Failure of this system results in an excess concentration of glutamate and may lead to neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) [41] , multiple sclerosis (MS) [42] , AD [43] and epilepsy [44] . Adenosine transporters are responsible for the efflux transporting of the purine nucleosides, guanosine, inosine and pyrimidine nucleoside [45] . Inhibiting the adenosine receptor signaling decreases macromolecules and inflammatory immune cells crossing the BBB. On the other hand, activation of the adenosine receptor by lexiscan enhances the permeability of macromolecules [46, 47] .
In terms of the drug delivery to the CNS, researchers are interested in organic anion and cation transporters of SLC superfamilies, including SLCO and SLC22 families (Fig. 1) [48] . Organic anion transporting
Luminal membrane
Abluminal membrane polypeptides (OATPs) of the SLCO family can carry anionic amphipathic molecules with a highly albumin binding [49] . The organic anion transporters (OATs), members of the SLC22 gene family such as SLC22A7, are also anion exchangers with luminal orientation. They are able to transport different drugs including benzylpenicillin, mercaptopurine and methotrexate into the brain [50] . Organic cation transporters (OCTs) such as SLC22A2 and SLC22A3 mediate the transport of small positively charged hydrophilic molecules such as desipramine, amantadine and memantine from the blood to the brain endothelim [51] .
Moreover, active efflux transporters in the BBB play roles in removal of endogenous and exogenous substances from the brain to the blood by consuming ATPs [52] . The efflux of toxic metabolites and drugs are mediated by ATP-binding cassette (ABC) proteins which are mostly localized in the luminal membrane of the BBB. Passively diffused small lipophilic molecules are among the molecules that are being pumped out from the brain by the efflux ABC transporters [53] . Although there are 48 different ABC transporters grouped into 7 sub-families, the main efflux ABC transporters in the BBB are Multidrug Resistance Protein (MDR such as P-gp, ABCB1), the Multidrug Resistance-associated Proteins (MRPs, ABCC1, ABCC2, ABCC4, ABCC5), and Breast Cancer Resistance Protein (BCRP, ABCG2) [54] .
The possible role of active efflux transporters in the pathogenesis of different neurodegenerative disorders such as epilepsy, PD and AD is increasingly investigated. For instance, efflux transporters expressed by ECs in the BBB together with other mechanisms such as the protease degradation, the flow of interstitial cerebrospinal fluid into the bloodstream, and the lymphatic drainage are the clearance mechanisms to remove amyloid-β from the brain. In-vitro human models [55] and animal studies [56] confirmed that P-gp plays a key role in the clearance of amyloid-β from the brain [57] . It is believed that the disease, life style and neurotoxicants have contributions in expression of these transporters in the BBB. The function of multidrug resistance protein (MDR) transporters in the BBB decreases with age which can deteriorates the clearance capacity of neurotoxic materials and elevates the risk of brain PD and AD disorders [58] . An upregulation of ABC transporters as neuro-protectors was related to the effect of transcription factors such as nuclear factor kappa beta [59] . On the other hand, some drugs can reduce the efflux transportation performed by P-glycoprotein and BCRP [59] . Inhibiting P-glycoproteins by P-gp modulators such as cyclosporine A, valspodar, and tariquidar showed a considerably higher uptake of drugs into the brain [60, 61] . Moreover, a low concentration of estradiol reversed the activity of BCRP-mediated transport in the brain of rodents [62] . Although the reports showed convincing results, there are critical concerns related to overlapping of substrate and inhibitor properties particularly for P-gp, BCRP and ABCG2 proteins [63] .
Receptor-mediated transcytosis (RMT) is a vesicular mechanism to transport low-density lipoproteins (LDL), transferrin, immunoglobulin G (IgG), cytokines and insulin across the BBB. This mechanism consists of receptor-mediated endocytosis, the movement in the intracellular space by the endosomal system, and exocytosis (Fig. 1) . Many researchers are interested in receptor-mediated transcytosis as an appropriate pathway for the delivery of drugs like recombinant proteins across the BBB [64] . A therapeutic protein like insulin is conjugated to antibodies against specific receptors on the BBB to undergo RMT-based drug delivery to the brain. For instance, LDL receptor-related protein-1 (LRP1) plays an important function in the clearance of amyloid-β from the brain. A relatively high level of copper can disturb LRP1-mediated clearance of amyloid-β and is considered as a contributing factor in AD pathology [65] .
Caveolae-mediated transporters are cholesterol sensitive vesicular carriers present on the plasma membrane of ECs. Caveolin proteins contribute to endocytosis, transcytosis and signal transduction. Theseproteins contain receptors for insulin and albumin as well as glycation end products (RAGE) as the primary transporter of amyloid-β from the blood circulation into the brain [66, 67] .
Ion transporters are essential for the neuronal and synaptic functions. Although the concentration of different ions such as potassium in blood plasma can change significantly, they are maintained at a relatively constant level by the BBB to provide optimal ionic composition [31, 68] . A high density of mitochondria on the BBB reflects a high degree of energy consumption by active ATP-dependent transporters such as ion pumps [69] . The sodium pump, sodium-potassium-two chloride cotransporter (NKCC), sodium-hydrogen exchanger (NHE), chloride-bicarbonate exchanger (CBE), and sodium-calcium exchanger (NCX) are the primary ion transporters at the BBB [3] . CBE not only regulates the active secretion of bicarbonates across the BBB but also adjusts the intracellular pH in the endothelium together with NHE [70] [71] [72] [73] .
BBB transport mechanisms and drug development
The treatment of neurological disorders and brain cancers requires bypassing the BBB barrier for effective delivery of drugs to the CNS [74] . A few small molecular therapeutics have been introduced for treating epilepsy, schizophrenia, and chronic pain [75, 76] . Almost all available drugs for the brain are small lipid-soluble molecules [45] . However, improving the lipid solubility of a drug for increasing its permeability in lipid membranes has two main constraints, namely, chemical structure considerations (such as molecular weight) and hydrogen bonding of the drug. These constraints limit the success of drug candidates in treating neurodegenerative disorders. The higher molecular weight of the drugs, the lower its penetration into the tissue and cells. Moreover, the membrane permeability reduces exponentially with an increase in the hydrogen bonds on the solute [28] . Blocking the hydrogen functional groups not only leads to a rapid hydrolysis in the body but also decreases the drug efficacy [45] . It is possible to couple the peptide or protein drugs to a vector, which is normally able to pass the BBB by a receptor-mediated transporter [77] . To enhance the drug delivery into the brain, available transport mechanisms on the BBB, termed as Trojan horse technologies, have been employed but due to the lack of appropriate models for the detailed analysis of transport mechanisms, the efficacy of drug transport through the complex BBB is still limited.
BBB dysfunction and brain diseases
BBB dysfunction is associated with a large number of CNS diseases with significant health, social and economical burdens. It is generally believed that the normal function of the BBB is disrupted upon changes in the CNS environment and during the occurrence or progression of these diseases [78, 79] . Stressors such as protein misfolding, inflammation within the brain elicit a cascade of events leading to the disruption and leakage of the BBB. On the other hand, triggers may come from the periphery. circulating toxins or inflammatory cells might destroy the BBB and invade the immune-privileged environment of the brain to cause neuronal dysfunction and degeneration. For instance, an increased infiltration of CD4 + T lymphocyte in the brain observed in mouse models of multiple sclerosis contributed to neurodegenerative processes [78, 79] . Infiltration of pathogenic antibodies and T-cells could also enter the CNS in ALS [80] . Finally, a destruction of neurons and astrocytes by infiltrated CD8 + T-cells is part of the pathogenic process in Rasmussen encephalitis [81] . In this section, we will review BBB dysfunction observed in the most common neurological diseases and conditions.
Alzheimer disease (AD)
AD is a prevalent neurodegenerative disorder and the most common form of human dementia. The disease is mainly characterized by the accumulation of neurotoxic amyloid-β peptides derived from the amyloid precursor protein APP and of neurofibrillary tangles made up with the cytoskeletal protein Tau [82] . One of the first identified BBB anomalies in AD subjects was the increased permeability [83] . Furthermore, the changes in brain vessels morphology, vascular density, increased mitochondrial content and pinocytosis of brain ECs were observed in AD patients compared to healthy controls [84] . At the molecular level, the intracellular adhesion molecule-1 (ICAM-1) increases in the capillaries and the neocortical extracts from AD brains [85] . This upregulation is hypothesized to activate the cerebral endothelium and increase the permeability of the circulating cells and molecules into AD brains [86] . Alterations in brain ECs as well as changes in pro-inflammatory cytokine TNFs, apoptotic marker caspase-3, and the tight junction proteins ZO-1, claudin-5 [87] [88] [89] [90] likely participate in local breakdown and dysfunction of the BBB [86, 91, 92] . Alterations of the BBB's functions not only reduce the ability of the brain to clear amyloid-β but also increase the access of toxic molecules and immune cells to the brain [93] . Together with glial and neuronal dysfunctions, the BBB leakage is likely contributing to mild cognitive impairment, structural disturbance, and disrupted sensory response [85] .
Parkinson disease (PD)
PD is the second most common neurodegenerative disorder [94] . Initiation and progression of PD occur mainly by a progressive loss of neuromelanin-containing dopaminergic neurons in the ventral midbrain. Such loss is associated with the presence of Lewy bodies composed of α-synuclein neurofilaments and ubiquitin. A continuous accumulation of misfolded α-synuclein ultimately leads to an apoptosis of neurons [95] . In vitro and clinical studies have shown that α-synuclein deposition has a crucial effect on the BBB integrity in PD [96] [97] [98] [99] . The uptake of drugs such as [11C]-verapamil that does not usually cross the BBB was enhanced in PD patients due to the BBB breakdown [96] . In addition, the defects in cerebral blood flow in PD patients resulted in an increased BBB permeability [97, 98] . Similarly, different neurotoxic elements such as oxidopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) that induce PD via a disruption in dopaminergic and noradrenergic neurons disrupt the BBB [100, 101] . Lastly, activated astrocytes and microglia secrete specific cytokines that can cause rearrangements of proteins in TJs of ECs, and contribute to neurodegeneration in PD [102, 103] .
Amyotrophic lateral sclerosis (ALS)
As the most common form of human motor neuron disease, ALS affects 2-3 individuals per 100,000 annually [104] . The BBB and bloodspinal cord barrier (BSCB) are damaged in ALS patients [105] . A reduction in the expression of proteins such as occludin and ZO1 in ECs [106] , a drop in perivascular occludin and collagen IV, perivascular deposits of erythrocyte-derived hemoglobin and hemosiderin, as well as dissociation of astrocyte end-feet from the endothelium are observed in spinal cord of ALS patients [107] . All these defects preceding the BBB/ BSCB disruption, and erythrocyte extravasations may ultimately cause neuronal loss [107, 108] . Recently, in vivo studies of transgenic rodents expressing mutant isoforms of human superoxide dismutase [Cu-Zn] (SOD1) linked to ALS, found that the BBB/BSCB breakdown occurs at the early stage of the disease and is worsened with the disease progression [109, 110] . In these mutant animals, the mRNA expression of TJ proteins and the basement membrane protein agrin reduces, leading eventually to an increased microvascular permeability of the BBB/BSCB [110] . Finally, dysfunctional signalling in pericytes of ALS mice damages the brain vasculature (including BBB and/or BSCB disruption with accumulation of plasma proteins and erythrocyte extravasations) prior to neuronal alterations [111, 112] .
Epilepsy
The BBB function can change by brain insults such as status epilepticus (SE) or traumatic brain injury. The BBB leakage occurs within minutes after SE and persists for several hours or days [113] . An increased permeability of the BBB can last several weeks, months, or even years, and this may be associated with abnormal Electroencephalography (EEG) activity [114] . BBB leakage may also lead to an enhanced excitability via an altered glial potassium buffering and brain inflammation that in a positive feedback loop, can further decrease BBB performance [115] . Moreover, besides the severe loss of BBB function, extravasations of serum albumin into capillary ECs, basal laminal, and neuropil are also observed in epilepsy [116] .
Current treatments of brain diseases targeting the BBB
There is currently no pharmacological treatment to stop or reverse neuronal damage in neurodegenerative diseases. Some treatments may attenuate cognitive and behavioral symptoms but none repairs damaged tissues. Obstacles in developing effective treatments include the long time required to observe the effect of investigational treatments on disease progression, the high cost of drug development, and the challenging access to the brain protected by the BBB. Immunotherapy is a privileged approach for the treatment of neurodegenerative diseases [117] . Several studies have documented the ability of Aβ antibodies to disaggregate misfolded amyloids in vitro [118, 119] and in AD animal models [120] [121] [122] [123] [124] [125] . However, in clinical trials, most AD patients immunized with Aβ peptide (AN-1792) were not receptive to the treatment, indicating a relatively unsuccessful approach [126] [127] [128] .
In PD, L23,4-dihydroxyphenylalanine (L-DOPA) is used as standard treatment to modify the permeability of BBB and alter its metabolism [97, 129] . As a result, L-DOPA can slow the rate of clinical PD progression. [130] Along this line, therapeutic strategies aiming to restore BBB function via inhibition of TGF receptors, leukocyte-vascular interaction, IL1R or the mammalian target of rapamycin (mTOR) pathway, show a great promise in experimental models of epilepsy [131] [132] [133] [134] . Despite the enhanced permeability of BBB in epileptic patients, some patients are drugs-resistant. One of the reasons for this setback is the upregulation of multidrug transporters, like Pgp, at the site of seizures which takes the drug out of the lesion site [133, 134] . Finally, changes in the expression profile of microRNAs in experimental epilepsy models (particularly miR-21, miR-146, miR-155, miR-221 and miR-222) can alter BBB permeability and/or induce brain inflammation [115] . Interfering with these specific miRNAs could modulate BBB performance and epileptogenesis. So far, there is no treatment targeting BBB/BSCB in ALS.
In vivo BBB analysis
The comprehensive understanding of neurodegenerative diseases needs appropriate testing protocols and characterization techniques to provide ample clarification on the mechanisms underlying disease progression and the pathways of drug effect in disease prevention [135] . A large number of different in vivo human and animal testing of the BBB permeability have been developed to characterize the effect of different constituents of the BBB involving cells, molecules, proteins and genes on the regulation or disruption of BBB permeability [136, 137] . These in vivo BBB tests have been reviewed by others and are beyond the scope of this paper. We briefly discuss the in vivo BBB tests that deal with neurodegenerative diseases and overview the human BBB functions in diseased brains.
BBB in AD models
The known AD animal models are transgenic dementia models like tau protein models, amyloid-β models, secretase models, ApoE models, and axonal transport models which simulate different pathological aspects of AD such as over-expression of human amyloid precursor protein (hAPP) [136, 137] . A majority of in vivo AD animal tests that considers BBB function as one major part of the study, had a particular focus on characterizing the function of capillary proteins like p-gp, lipoproteins, and the genes expressing these proteins with a principal role in the clearance of misfolded proteins from the diseased brain [135] . Using in vivo mice models, P-gp has been discovered as one of the most prominent components of the BBB in moderating amyloid-β deposition expressed by two genes of MDR 1 and MDR 2 and with 80% similarity to human MDR function [138] [139] [140] . The inhibition of P-gp activity in P-gp-null mice models increased amyloid-β levels in the brain within hours of inducing AD in mice [140] . To achieve a predictive simulation of human neurodegenerative diseases, P-gp was chemically alleviated in mice using selective inhibitors of P-gp, such as PSC 833 (Valspodar), GF120918 (Elacridar), and LY335979 (Zosuquidar) [140, 141] . In addition, the magnitude of P-gp-based drug interactions were studied by modeling the inhibitory activities of P-gp in rat's BBB via the incorporation of verapamil as the P-gp substrate and cyclosporine A (CsA) as the P-gp inhibitor [141] . Animal models have also been used to investigate the function of P-gp in the presence of different drugs [139, 142, 143] . In addition, several PD animal models have considered the contribution of the BBB in pathology of PD through investigating the role of the BBB in penetration of neurotoxins associated with PD ( Fig. 2) [144, 145] . Besides the toxin-based PD animal models, PD genetic models have been also developed to investigate the molecular pathways involved in PD due to genetic parameters [146] . However, the contribution of the BBB in PD pathology of genetic models needs further investigation via better models with the ability in systemic analysis of involved parameters [147] .
Disregarding the type of neurodegenerative disease interacting with the BBB, insects and zebrafish have represented high-throughput (HT) systems with the ability of testing the BBB permeability. In case of insects, two models namely locust model and fruit fly model have been successfully developed [148, 149] . The epithelial BBB barrier in Fruit fly mimics the human BBB to some extent, given the 60% similarity of its gene sequence to human. However, the barrier in fruit fly is epithelialbased. Moreover, its BBB has the components of TJ and ABC transporters like Mdr65, which resembles the function of P-gp in human (Fig. 2b) [150] . Zebrafish is another proper BBB model vastly used in different biological and drug discovery studies (Fig. 2a,c) . The superiority of zebrafish models is due to the presence of ECs layer that act as the same as human BBB in permeability and its ability to visualize the molecular transport through the fluorescent microscopy [148, 151] .
In vivo drug delivery across the BBB
To treat brain diseases, drugs need to be delivered at the therapeutically active concentration to the CNS. The BBB as the primary obstacle plays an important role since it does not let approximately 98% of drugs reach to the CNS, leading to the failure of a majority of promising CNS drug candidates [155] [156] [157] . Different strategies have been developed during the last decade to improve the drug delivery efficiency into the CNS such as nasal delivery, local delivery and systemic delivery [155, 158] . In this section, we discuss the systemic delivery since it is more relevant to circumventing the BBB compare to other techniques [155, 158] . The systemic in vivo delivery within the brain capillary endothelium is primarily based on the endogenous transport systems such as carrier transporters, active efflux transporters and receptor transporters, or relies on other techniques like stem cell therapy [159] [160] [161] [162] . Carrier transport regimes implement nano-carriers such as exosomes, micelles, liposomes and various nanoparticles, opening the avenue for treating neurodegenerative diseases [163] .
Exosome-endogenous nano-vesicles are drug nano-carriers that enable the crossing of non-transportable drugs such as siRNAs, chemotherapeutic agents and proteins through the BBB [164] . Exosomes have been successfully tested for AD treatment for knocking down betasecretase 1 (BACE1) as one regulator of AD pathogenesis (Fig. 2d ) [152, 153] . Also transferrin receptor (TfR) was used to deliver antibodies across the BBB in the primate brain to decrease the level of accumulated amyloid-β proteins [165] . The results of testing TfR/ BACE1 by specific antibody variants proved that a reduction in the TfR Fig. 2 . In vivo BBB analysis. The schematic comparison between the BBB of a) vertebrates like zebrafish and b) non-vertebrates like fruit-fly [148, 151] , c) Western blot analysis of the cross-reactivity between anti-ZO-1 antibody and zebrafish ZO-1 proteins. In both zebrafish whole embryo lysates (3 dpf) and adult brain lysates, anti-ZO-1 antibody recognized a band that exhibits a similar migration to human ZO-1α+ (1748 amino acids), suggesting that it might be zebrafish ZO-1.2/TJP1.2, d) In vivo delivery of siRNA with targeted exosomes results in a brain-specific gene knockdown. Animals were euthanized 3d after injection, and cortical sections were assayed with BACE1 qPCR (left), BACE1 western blot (right) [152, 153] , e) MRIgFUS allows the passage of GFP-expressing through the BBB and entry to the brain. The targeted delivery of cells via detecting GFP-positive cells in the left striatum (A,B) and their absence in the untreated striatum (C,D). Stem cells in the hippocampus were detected in the pyramidal cell layer (E, arrow) and dentate gyrus (F, arrow) [154] .
binding affinity improves the brain uptake. The details of BBB crossing nanocarriers are discussed in Section 6.3.2. Stem cells have also shown promising for the treatment of brain diseases where they were delivered to the brain noninvasively through the BBB, discussed in Section 5.2.3 in more details (Fig. 2e) [154, 166] .
Challenges on analysis of in vivo BBB function
Human BBB-related studies are restricted to post-mortem investigations and imaging techniques such as MRI and positron emission tomography (PET) with a limited resolution [167] . Different animal injury models with a limited translational significance and high cost have been developed to characterize the relationship between brain diseases and loss of the BBB integrity. Nevertheless, the mechanisms underlying the BBB disruption and maintenance of the BBB integrity are still poorly understood [168] . In addition, in vivo BBB studies are not easily accessible since the BBBs are present in a complex microvascular network within the brain and therefore it is difficult to isolate it for further targeting specific mechanisms [169] . Furthermore, the complex cellular interactions within the brain parenchyma make it difficult to recognize the specific contribution of cellular components and pathways to the BBB function [170] . On the other hand, in vitro models enable systemic analyses of different parameters and components, such as brain ECs, neurons, astrocytes, glial cells as well as the dynamic flow and shear stress. In vitro models assist uniquely in evaluating the efficacy of innovative methods for BBB disruption and a better understanding of drugs or cells delivery through the BBB via different transport systems [171] [172] [173] .
In vitro models of BBB
The primary goal of developing an in vitro human BBB model is to reproduce different aspects of in vivo BBB similar to that in the brain microvasculature for early stage screening of potential CNS drugs and BBB permeability evaluation [174] [175] [176] [177] [178] . The development of in vitro BBB models is crucial to facilitate predicting the permeability of druglike molecules through the BBB; to perform optimization and prescreening of drugs and gene delivery vectors; and to understand the relationship between neurological diseases and BBB dysfunctions [176, 177, 179] . In addition, the lower costs of in vitro models compared to in vivo studies and a minimal constrain in usage of different cell types provide an opportunity for systemic analysis of BBB function in HT systems [180] . The desirable properties of in vitro BBB models are summarized in Fig. 3 . To provide a predictive in vitro BBB model, it needs the expression of TJs to modulate the permeability. Their adequate permeability should be validated by a low permeability of sucrose or polar molecules that do not cross the BBB. In addition, the permeability should be selective based on the molecular weight and oil/water partitioning. Finally, the expression level of transporting proteins should be comparable to that of in vivo systems [174] [175] [176] [177] [178] [179] [180] .
General view of in vitro BBB setups
The in vitro BBB models could be significantly different in their designs. However, they usually contain components in common: a barrier between two liquids, composed of cultured cells on a semipermeable membrane; extracellular matrix (ECM) that is located between the barrier cells and the semipermeable membrane; and ideally the brain microenvironment (Fig. 4a,b) [174] [175] [176] [177] . For the permeability studies, the molecule or drug of interest is introduced into one of the liquid sections either in the brain side or the vasculature compartment, while its penetration through the barrier is characterized over time. In human body, collagen IV and laminins are the essential components of the vascular basal lamina. To mimic the brain vessels' basal lamina for in vitro models, a combination of cell adhesive materials is coated on the semi-permeable membrane [181, 182] . To introduce the brain microenvironment, brain parenchymal cells are cocultured on the opposite side of the semipermeable membrane or at the bottom of the tissue culture wells [175, [183] [184] [185] [186] [187] [188] . The in vitro BBB models in the form of 6-96 wells are usually called static models [176, 177, 179] while the dynamic models like microfluidic setups use a media flow to mimic in vivo shear stress essential for biomimetic BBB function [171, 172, 189, 190] .
BBB functions versus cell species
Non-human mammalian cells are the most widely used cells in building in vitro BBB models. Nevertheless, significant differences have been reported for BBB properties among different species. Cell lines of different species can be different in function and expression of key transporters [54, [191] [192] [193] . BCRP transporter (ATP binding cassette protein G2/ABCG2) is significantly predominant over P-gp in the BBB of humans versus rodents [192, 194] . Also the expression of proteins like GLUT3, ABCA8 and ABCA2 in human cells is reported to be higher compared to that of rodent [192] . While the expression of ABCG2/BRP is very high in the human BBB, its expression in the rodent BBB is relatively low [13, 192, 195] . The expression level of ABCB1 transporter has also been reported to be three-four folds higher in the mouse brain compared to human and monkey [54, 191, 192] .
The differences in the expression of some proteins are in direct relationship with the characteristics of the BBB permeability. The expression of claudin 5 is about two folds higher in rats, monkeys, cynomolgus and marmosets compare to humans [191] . Taking into account that claudin 5 is crucial in TJ formation in humans, one can argue the direct link between the expression of proteins and BBB function of human ECs. ABCC2, ABCC4 and ABCC5 are also more abundant in rodent, bovine and porcine brain capillaries than human [192, 196] . For drugs that function as substrates for the transporters (like antibiotics and anticancer agents), the difference in the abundance of transporters affect the BBB permeability [192, 196, 197] . Other reports also confirm the effect of differences in the protein expression on drug distributions in the CNS [193, 198] . The verapamil concentration in the brain is about four times higher in monkeys compared to rodents [193] . Since some drugs are substrates for more than one transporter (such as ABCB1 and ABCG2), the situation could be more sophisticated [198] . Besides the differences in the level of proteins' expression, the difference in affinity of the substrate to P-gp needs to be taken into account [198] . Altogether, to achieve biomimetic BBB models, it is worthwhile to put the emphasis on developing BBB models relying on human cells.
Primary cells
Primary brain ECs (BECs) from different species including human [187, 188] , mouse [185] , rat [184] , porcine [186] , bovine [175] and monkey [199] have been used in the design of in vitro BBB. [200, 201] Porcine BECs have shown the highest average TEER values, as high as 700 −800 Ω.cm 2 in both monocultures and cocultures [186] . Nevertheless, rodent and bovine coculture models represented reasonable TEER values up to 600-700 Ω.cm 2 [177, 200, 202] . Although human primary cells can be the ideal cells for drug delivery evaluation, some limitations cause serious difficulties in their application in HT tests [203, 204] . The isolation process of primary human cells is often expensive and sophisticated, and preparing the model using these cells is a sensitive and time-consuming process [203, [205] [206] [207] [208] [209] . In addition, the properties of cultured cells may be different from batch to batch, and the number of cells is not sufficient for HT examination [210] . Primary Fig. 4 . In vitro BB models. a) A diagram of key components of a 'generic' in vitro BBB model, including the ECs barrier that divides two compartments, the ECM that models the basement membrane, and the brain microenvironment that modulates the BBB phenotype of ECs [178] , b) A typical Transwell diffusion system made of a semi-permeable porous polypropylene or a polycarbonate membrane, acting as an interface between the luminal and brain compartments [180] , c) A variety of different configurations of the monoculture and coculture of cells recapitulating the interaction between the brain with the neovascular unit [259] , d) A capillary-venules model to simulate the dynamics of cerebrovascular physiology [260] .
human BECs usually function over limited passage numbers and present a low yield. They de-differentiate quickly and have patient-related heterogeneity. Furthermore, because of lacking the in vivo physiological factors within in vitro BBB models, after each passage, they lose some phenotypic expressions [211] . Consequently, the measured TEER values are low and not highly stable [211, 212] . Therefore, the usage of primary human BEC for in vitro human BBB models is still a challenge [178, 203, 204, 210] .
Immortalized cell lines
Aiming for testing larger compound libraries with a higher efficiency and lower cost, immortalized BEC cell lines have been developed using immortalization protocols for species, including rat, mouse and human [213] [214] [215] . Different immortalized human BEC lines such as BB19 [216] , hCMEC/D3 [214] , and hBMEC [217] have been utilized for in vitro human BBB modeling. BB19 human EC line has shown a high permeability to sucrose, indicating that this cell type is not a high-caliber choice for BBB permeability tests [218] . The human cerebral EC line of hCMEC/D3 is the most widely used and characterized cell line [214, 215] . Optimization of culture conditions and coculture of hCMEC/ D3 with astrocytes increased the TEER values up to 140 Ω.cm 2 [219] .
However, the protein expression pattern loses by removing cerebral ECs from their original environment and implementing the immortalization process. Compared to primary cells, the expression level of claudin 5, insulin receptor, JAM2, SLC2A1, ABCB1, LRP1, occludin and RAGE are dramatically decreased [220] . In addition, hCMEC/D3 cell line does not represent the dominant phenotype of ABCG2 transporter compared to primary cells [221, 222] . On the other hand, hBMEC cell line showed elevated TEER values compared to hCMEC and BB19, and expressed the key endothelial markers [216, 221, 223] . Further comparative studies over hCMEC/D3, hBMEC, and BB19 showed a TEER value as low as 45 Ω.cm 2 for all three models. The TEER value did not improve considerably even in the combination with immortalized human HBPCT pericytes [224] and/or SVG astrocytes [225] . It is noteworthy that BBB properties of immortalized cell lines also depend on the origin of cells. Barrier properties of immortalized cells belonging to rat usually function better compared to those from mouse but not as well as those from bovine and porcine origins [177, [226] [227] [228] [229] [230] [231] [232] . BBB models utilizing immortalized cell lines should be used with a caution as "representative" because of their significant phenotypical and genotypical divergence from primary cells [200, 220] . For instance, significant differences have been reported between transcriptomics of primary human BECs and hCMEC/D3 specifically for genes related to the DNA repair, RNA processing, mitosis and immune response, where they were up-regulated in hCMEC/D3 cell line [220] . Such differences in protein expression levels mainly resulted in the loss of TJ proteins, which limited their application in drug permeability assessment [233, 234] .
Human stem cell-derived BBB models
Utilization of stem cells to achieve differentiated BECs can be considered as one of the newest advancements in bioengineering of in vitro human BBB models [235] . During the differentiation and self-renewal of stem cells, they keep a homogenous genetic profile and drive other neural cells of neurons, astrocytes and pericytes from the same stem cell source [236] . Specifically, the hypothesis that neural stem cells are the real driver of BBB formation and development puts more emphasis on the application of stem cells for generation of in vitro BBB models [237] .
Human multipotent or pluripotent stem cells, like neural progenitor cells or hematopoietic progenitor/stem cells, have shown promising results for building in vitro human BBB models [236, [238] [239] [240] . Human pluripotent stem cells (hPSCs) have been recently employed to build an in vitro developmental BBB model [236] . BECs derived from hPSCs acquired BBB properties when co-differentiated with neural cells and provided appropriate cues, including those involved in Wnt/β-catenin signaling [236] . The resulting BECs presented many BBB characteristics such as TJ formation, appropriate expressions of nutrient transporters, and reasonable activities of polarized efflux transporters. BECs co-cultured with astrocytes acquired substantial barrier properties as measured by TEER and possessed a molecular permeability comparable with in vivo blood-brain transfer coefficients. However, one needs to keep in mind that the differentiation capacities of the hPSCs vary depending on the initial source of cells. Also no detailed information on the long-term stability of these cells is available, which may cause issues for drug screening [238] .
Human endothelial progenitor cells [239] and human hematopoietic stem/progenitor cells (HHSC) have also been used to develop in vitro BBB models [235] . Regarding the permeability studies of different molecules and drugs, the BBB model made of EPCs showed no clear correlation with the in vivo data. They also presented the optimal paracellular permeability only for a few days [239] . On the other hand, HHSCs resulted in a reproducible and stable human BBB model, where the in vitro pharmacokinetic results were well correlated with the in vivo data [235] . A new source of cells based on cord blood circulating endothelial progenitors (EPCs) was successfully used to acquire BBB properties [239] . Induction of human umbilical cord blood EPCs by appropriate stimuli was demonstrated to retain an immature phenotype, allowing them to differentiate in vitro further towards specialized BBB phenotypes [239] .
Monocultured, cocultured, static and dynamic models
Different cells play different roles in the BBB models. Parenchymal cells induce and maintain the BBB phenotypes, while pericytes induce the differentiation and reduce pinocytosis. Astrocytes also modulate the tightness of the BEC barrier [177, 179, 241] . Several different monoculture [210, 242] and coculture [243] [244] [245] [246] models have been developed to specifically take into account the effect of different cell types and ratios on the BBB function (Fig. 4c) . The coculture models consist of at least two different cell types [177, [247] [248] [249] . In another classification, depending upon the presence of shear stress, the in vitro models can be classified as static and dynamic models [168, [250] [251] [252] [253] [254] [255] .
Endothelial monocultures
The endothelial monocultures are the simplest in vitro BBB models. In such models, cerebral endothelial cells from different species like murine, porcine, monkey, rat, bovine and human are cultured on a semi-permeable membrane, where the BBB permeability is measured across the membrane (Fig. 4c) [210, 242] . The primary advantages of monocultured BBB models are their simple fabrication and moderate costs, which makes HT screening feasible [242] . However, in the absence of other cellular components of the BBB, especially astrocytes and pericytes, the models represent relatively low TEER values [242] . More importantly, the expression of proteins like P-pg, contributing in conferring the BBB phenotype, may get disturbed in such models [256] . These changes cause significant abnormalities in BBB permeability. To overcome this limitation, dexamethasone or hydrocortisone were added to the culture media to improve BBB tightness [257, 258] .
Coculture of BECs with astrocytes
While monoculture BBB models are informative for the permeability tests, cocultured BBB models show more biomimetic features by maintaining barrier features and representing the complexity of cell-cell and cell-matrix interactions [243] [244] [245] [246] . The coculture models incorporate ECs, astrocytes, pericytes, and ECM [177, 261] .
Astrocytes in the neurovasculature are not in a direct contact with ECs but affect the transporters' expression, the inter-endothelial junctions, and thus the BBB permeability [262] [263] [264] . Different in vitro BBB models have been developed to take into account the effect of astrocytes on the BBB function [208, 265] . In one approach, astrocytes were cultured on the opposite side of the semipermeable membrane to crosstalk with ECs. In another approach, astrocytes or astrocyte-conditioned medium containing soluble material were incorporated at the bottom of the wells enabling the soluble factors to induce their effects (Fig. 4c ) [208, 265] . The later approach showed a better permeability response [266, 267] . Rodent ECs cocultured with rodent glial cells are the most widely used combination [185, 208] . In vitro BBB models cocultured with astrocytes represent good barrier properties with the correlation coefficient as high as 0.98 compared to the in vivo data [177, 207, 226, [268] [269] [270] and changes the expression of above 50 proteins involved in the protein metabolism, protein modification, and the cell structure and motility [243, 244] . Astrocytes can upregulate the efflux transporters like ABCG2 and ABCB1 [271, 272] .
Coculture of BECs with pericytes
Pericytes are the closest contacting neighbors of BECs within the in vivo BBB. They play different roles in the immune response, contraction, phagocytosis and angiogenesis in addition to participating in formation of the basement membrane by synthesizing collagen IV, laminin and glycosaminoglycans [22, 245] . Pericytes are also capable of altering the paracellular permeability by regulating the genes like occludin and transforming growth factor beta (TGF-β) in cerebral ECs [23, 246] . The permeability function of pericytes-containing BBB models have shown a superior performance compared to astrocytes-containing models [183] . Pericytes can also induce the functional activities of transporters like ABC [210, 273] . Nevertheless, several reports indicate that the effect of astrocytes and pericytes in coculture models strongly depends on the origin of cell types [23, 183] . In addition, a direct contact to ECs for pericytes in coculture models is essential to induce enhanced BBB properties while astrocytes can act from distant [249] .
Tri-culture models of BBB
The fact that both astrocytes and pericytes have crucial roles in modulating the function of brain ECs has led to the development of triple coculture models [210] . In tri-culture BBB models, ECs are usually cultured on top of the semipermeable membrane; pericytes on the lower side; and astrocytes at the bottom of the well [177, 183] . In addition, neurons have been utilized in triple models [177, [247] [248] [249] . Putting all together, tri-culture BBB models can result in a better mimicking capacity of the in vivo conditions especially via a better expression of TJ proteins, a lower permeability of compounds like sucrose or inulin, and a higher measured TEER values [180, 274] . On the other hand, these tri-culture in vitro models still lack the presence of shear stress and blood cells [250, 251] .
Dynamic in vitro BBB models
Beyond the existing abovementioned BBB models, or so-called static BBB models, dynamic BBB models have been developed to mimic the blood flow of in vivo conditions [168, [250] [251] [252] [253] [254] [255] . The flow is introduced to induce a shear stress of approximately 1-20 dyn/cm 2 to ECs in order to improve barrier properties [168, 255] . These models allow designing quasi-physiological experiments. One approach to build dynamic BBB models is to culture ECs on a semipermeable support, fold the flexible support to form a hollow fiber construct, and expose the 3D BBB construct to media flow. Further developments have been made on dynamic in vitro BBB models via the coculture of BECs with muscle cells (Fig. 4d ) [189] . However, the need for a large quantity of cells required to cover capillaries and to generate detectable cytokines and molecules was one of the main drawbacks of the models [189] . Dynamic BBB models also helped to investigate the effect of blood-derived human macrophages in the permeability of cultured brain capillary ECs (BCECs) [275] . The regulation of the barrier function of BCECs in a noncontact coculture system was examined using a dynamic BBB model containing primary BCEC monolayers grown on porous polycarbonate membranes. The characteristic properties of the BBB formed by BCECs are modulated by their microenvironment, however the cellular sources of the inducing signals are still unclear. Macrophages adjust BBBspecific functions in cultured BCECs and therefore could be part of BCECs microenvironment to modulate the BBB-specific properties in vivo. Such in vitro dynamic BBB models tested under physiological flow have also been used to unravel the cellular and molecular mechanisms underlying the multistep extravasation of activated CD4 + and CD8 + T cells across the BBB [276] . The results showed that higher numbers of CD8 + than CD4 + T cells were arrested on and crossed the endothelium under noninflammatory and inflammatory conditions. Despite significant advances in the development of in vitro BBB models listed above, there are still constraints associated with these models in producing biomimetic BBB models. The BBB constructs of Transwell systems are still 2D planar models with less resemblance to the 3D microscale capillary architecture of the BBB in vivo. Because of the lack of a microscale environment, there is a certain limit in producing microscale capillary networks with biomimetic branching and flow conditions, as a pre-requisite for providing long-term co-culture of cells. Moreover, the lack of appropriate microenvironment has been always restraints for further biomimetic characterizing the flow of molecules, immune cells and microbiome through the capillaries and investigating their interaction with the BBB for disease modeling purposes.
New Technologies for development and testing of biomimetic BBB models
A variety of different technologies such as microfabrication, microfluidics, nano-carrier drugs, miniaturized HT systems, biosensors, and integrated manipulation systems have contributed to the development of biomimetic BBB models and advanced testing of drug candidates penetrating through the BBB. In this section, we discuss the current and future impact of these technologies on the modeling and testing of in vitro BBB models.
Microfluidic models
With the advancement of different microscale technologies, numerous microdevices have been developed to provide in vivo-like microenvironments and 3D culture models [212, 277, 278] . Microfluidicbased models have many advantages over existing in vivo and in vitro static and dynamic models: (1) provide a miniaturized system with considerably lower costs and timescales; (2) consume a smaller functional volumes for a faster media exchange and material conservation with shortened times to steady-state levels; (3) generate parallel, controlled and repeated microenvironments; (4) dynamic microenvironment provides shear stress stimulation to cells allowing the improved analysis of test compounds and controlled delivery compared to static models; (5) incorporate a thinner culture membrane to reduce the distance between co-cultured cells; (6) allow a more HT approach to experimentation; and (7) enable the integration into biosensors for long-term monitoring of BBB functions.
Microfluidics technology has recently been employed to overcome several obstacles to building biomimetic in vitro BBB models via miniaturizing the system, decreasing the quantity of required cells and media, and simultaneously inducing shear stress effects [172, 190, [279] [280] [281] . For microfluidic-based BBB models, a semipermeable membrane is located between two microchannels, allowing the media flowing over cultured cells. The integration of electrode pairs to both the top and bottom microchannels enables the online measurement of TEER values [172] . For instance, a microfluidic model with the shear stress of 5.8 × 10 − 1 Pa has shown an increased TEER value of up to 120 Ω·cm 2 compared to the value of 36 Ω·cm 2 in the static model [171, 172] . Towards developing an integrated microfluidic-based biomimetic BBB model, Booth and Kim [282] presented a permeability analysis of neuro-active drugs and its correlation with in vivo brain/plasma ratios in a dynamic microfluidic BBB (uBBB) model. The permeability and TEER values were measured for seven different neuro-active drugs (Ethosuximide, Gabapentin, Sertraline, Sunitinib, Traxoprodil, Varenicline and PF-304014) in both dynamic (microfluidic-based) and static (Transwell-based) conditions, either with brain ECs in monoculture or in co-culture with glial cells. To characterize the permeability of the uBBB, drugs with a constant concentration were run through the luminal channel. The permeability was computed from the measured abluminal concentration in the sample volume (Fig. 5a ). For all seven drugs, dynamic and co-culture models respectively resulted in a lower permeability and significantly higher TEER values compared to static [171] , b) SyM-BBB model consisted of apical and basolateral sides separated by pillar gaps in xy plane. The apical side contained ECs while basolateral side contained astrocytes. The results showed a significant upregulation of ZO-1 levels in SyM-BBB compared to the Transwell system [280] , c) The schematic diagram of brain tissue spheroids generated within the microfluidic chip, applicable to model the interaction of neural cells with misfolded proteins in AD model [283] .
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Journal of Controlled Release 273 (2018) and monoculture models. Their results indicated the feasibility of dynamic microfluidic BBB model for predicting the BBB clearance of pharmaceuticals. Prabhakarpandian et al. [280] presented a synthetic microvasculature BBB (SyM-BBB) model. The microchip was made of a optically clear microfluidic device with a two-compartment chamber with the size of the human microcirculation. The chamber allowed the sideby-side positioning of apical and basolateral compartments. The apical side was seeded with ECs and the basolateral side supported the culture of neuronal cells under the conditioned media (Fig. 5b) . Immortalized rat brain EC line (RBE4) was seeded in SyM-BBB and cultured under a flow of astrocyte conditioned media. Biochemical analysis showed an upregulation of TJ molecules, and permeation studies presented an intact BBB. The primary benefits of the SyM-BBB include: (1) realistic microcirculatory dimensions, (2) physiological fluid flow and shear stress, (3) oxygen-permeable substrate that allows a long-term in situ cell culture, and (4) real-time optical monitoring. SyM-BBB platform enabled a predictive screening, evaluation and optimization of the ability of a drug candidate to permeate the BBB. The application of this platform along with the complementary in silico approaches could accelerate the development of CNS therapeutics [280] .
Regardless of ECs configuration, microfluidics has been used to mimic brain tissue microenvironment by coculturing neural cells embedded within appropriate ECM in the form of neurospheroids [283] . Concave microwell arrays offer the advantages of homogeneous spheroidal micro-tissue formation and appropriate size control [277, 283, 284] . A constant flow of fluid resembling the interstitial space of the brain was provided over neurospheroids to deliver nutrients and misfolded proteins to cells (Fig. 5c) . With their proposed brain-on-chip, they tested toxic effects of amyloid-β, generally considered as the primary contributor in AD pathology. Amyloid-β introduced into microfluidic chip under an osmotic micropump reduced the viability of neurospheroids and led to a significant disruption in neural networks compared to static conditions. A future incorporation of the endothelial layer to this model is expected to provide a biomimetic brain-vessel model useful to study the clearance mechanism of misfolded proteins from the brain through active or passive BBB transport mechanisms. Griep et al. [172] presented a model of microfluidic-based BBB relying on immortalized human hCMEC/D3 with the integrated TEER. The barrier function is modulated both mechanically by exposing it to a fluid shear stress and biochemically by a stimulation with tumor necrosis factor alpha (TNF-α). The results demonstrated that hCMEC/D3 Fig. 6 . Advanced technologies of tissue engineering, microfluidics and biosensors for the development of BBB-on-chip, a) Multilayer vascular-like structures as tubular channels fabricated in gelatin-methacryloyl (GelMA) hydrogels [289] , b) The coculture construct of astrocytes, pericytes and BECs within a hollow collagen tube to model the 3D human BBB [287] , c) The integration of oxygen and pH sensors to the microfluidic bioreactor [293] , d) The integration of electrochemical biosensors to microfluidic bioreactors for the long-term detection of biomarkers [294] . cells were functional in the microfluidic device up to 7 days, and that these cultures showed comparable TEER values with the well-established Transwell assay. The results demonstrate proof-of-principle microfluidic-based experimentations for modeling the BBB as well-suited models to investigate brain capillary barrier functions in details and evaluate the drug passage, to finally gain insights into the treatment of neurodegenerative diseases.
BBB-on-chip
Recent developments in microscale engineering technologies have provided opportunities for microfluidic systems to bioengineer different organs. Organs-on-chip platforms have shown success in combining technologies of microfluidics and tissue engineering to provide spatiotemporal chemical gradients and dynamic mechanical environments of living organs [285] . They have been used to develop biomimetic tissue organs as stand-alone models for drug discovery applications [286] [287] [288] . An organ-on-chip platform consists of a few cell types cocultured in 3D hydrogels placed in controlled conditions within layers of a microfluidic chip, while mimicking the complex cell-cell and cellmatrix interaction [289] . The new generation of microfluidics-based organ-on-chip platforms are expected to provide complex structures and networks, and 3D microenvironments for supporting phenotypic cell behavior in tissue organs and in vitro diseases.
An ideal in vitro BBB-on-chip model is expected to consist of 1) a 3D multilayer hydrogel with the layers of ECs, astrocytes, pericytes and muscle cells; 2) a vasculature chamber for delivery of the blood or medium to the cell-laden hydrogels under controlled hydrodynamic flow, osmotic pressure, and shear stress; 3) a brain tissue chamber for either collecting the molecules transported from vessels across the BBB to the brain chamber or vice versa; and 4) biosensors within a closeloop system need to be integrated into the microfluidic BBB model to enable the long-term monitoring the BBB microenvironment. These biosensors should be able to detect biophysical parameters of osmolarity, pH, and oxygen concentration as well as biochemical parameters like biomarkers, cytokines and drug molecules. While the ideal BBB-onchip model has not been yet implemented, the progress in both microfluidic-based models of BBB and tissue engineering of 3D vascular systems is promising towards the development of idea BBB models.
The microfluidic-based BBB models discussed in Section 6.1 have inspired researchers to develop new advanced biomimetic BBB models. Several groups including ours have used advanced tissue engineering approaches to develop multilayer vessels supporting the engineering of multicellular hydrogels (Fig. 6a) [289] [290] [291] [292] .
In a successful attempt to use 3D hydrogels for microengineering of the 3D BBB construct, a cylindrical collagen gel contained in a hollow central lumen were placed inside a microchannel, where the primary human brain microvascular ECs were cultured on the gel's inner surface and exposed to the media flow. The effect of coculture of astrocytes and pericytes with ECs were further analyzed to explore the ability of this 3D BBB model to identify the role of each cell type in the neuroinflammatory response (Fig. 6b) [287] . We integrated physical oxygen Fig. 7 . Engineered capillary networks and multi-organ on-chip platforms with the potential to develop biomimetic BBB models and to investigate the cross-talk of brain with other organs, a) Microfluidic networks with different shapes and sizes in gelatin [295] , b) A branched, bifurcated microvascular network, much like exist within the human dermal microcirculation [296] , c) The microfluidic device with two microfluidic circuits. Arrows indicate a fluid flow direction within the circuit, S-skin culture compartments, L-liver culture compartments [305] , d) The microfluidic four-organ-chip accommodating a surrogate blood flow circuit and an excretory flow circuit. The four tissue culture compartments include intestine (1), liver (2), skin (3), and kidney (4) tissue [306] , e) The multi-organ chip accommodating two microfluidic circuits interconnecting human liver construct and neurospheres [307] , f) The multisensory integrated multiorgans-on-chip platform for real-time and long-term monitoring the crosstalk of liver and heart organs through the vasculature, for testing the direct and side effects of drug candidates [308] .
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Journal of Controlled Release 273 (2018) and pH biosensors to microfluidic bioreactors for the long-term monitoring of tissue microenvironment (Fig. 6c ) [293] . Moreover, an integrated electrochemical biosensor was also integrated to microfluidic bioreactors to detect biomarkers from tissues embedded within the microfluidics (Fig. 6d ) [294] . It is believed that a similar integration of both physical and electrochemical biosensors to the engineered multilayer vasculature within microfluidics will provide a significant advancement toward obtaining the next generation of biomimetic microfluidic-based BBB models.
The currently available BBB-on-chip models rely on designs with a porous membrane sandwiched between two simple microchannels. While these simple planar designs have been informative for basic permeability studies, they do not mimic the architecture and 3D structure of brain capillary network. The advanced micro and nanotechnologies for the engineering of different tissues including vessels have enabled the fabrication of complex constructs and 3D vasculature systems in a variety of different sizes (Fig. 7a,b) [295] [296] [297] . Taking the advantage of microfabrication to make circular vascular networks with a variety of different capillary sizes from one millimeter down to a few micrometers, one can make brain capillary networks exposed to a wide range of shear stresses over ECs [295, 296] . Such platforms can be a support for systemic analysis of the impact of hydrodynamic pressure, osmotic pressure, and shear stress on the BBB function.
The impairment of the BBB is not necessarily resulted from the malfunction of brain tissue. The BBB actively interacts with the blood circulation and in consequence cross-talks with other organs. Injury of many organs has shown to be effective in BBB dysfunction [298] . For instances, patients with the acute respiratory distress syndrome present a degree of cognitive and neurological dysfunction as a secondary marker of injury, potentially via common mediators during brain-lung interactions through the BBB [298] . In addition, the permeability of the BBB was considerably enhanced after burning the skin, possibly due to the release of substances like vasoactive originating in the damaged tissues [299] . An increase in the cerebral blood flow elevated the ammonia uptake to the brain tissue [300] . Toxins of the hepatic coma such as mercaptans, phenol, ammonia and methyl octanoate increased the BBB permeability significantly [301] . Studies using in vitro BBB models have also indicated that hypoxia causes an increased BBB permeability [302] . TNF-α was shown to be effective in altering the permeability of the BBB during acute liver failure (ALF) [303] . ALF disrupted the BBB and increased the susceptibility to stroke [304] . Characterizing the interaction of the brain with other organs needs a reliable and predictive model to mimic human physiology and disease pathology. While most of studies have been implemented via in vivo animal models, they suffer from weak physiologically relevance to humans, system complexity, high cost, ethical concerns associated with human studies, and new legislations limiting in vivo studies. There is an increasing demand to establish biomimetic human models to investigate the cross-talk of the brain with associated organs mainly liver, lung, gut, kidney and heart. Such models should faithfully mimic the in vivo microenvironment and be sensitive and cost efficient.
Organ-on-chip platforms not only provided opportunities to develop biomimetic human organs but also to interconnect multiple organs [305] [306] [307] 309, 310] . Several groups including ours have developed multi-organs on chip platforms and shown the capability of generating 3D tissues synthesized from different constituting cells interacting with a common media or the cellular barriers to bridge the gap in systemic characterization for disease modeling and drug discovery (Fig. 7c,d ) [305] [306] [307] 310] . They have been able to provide cross-talks of two to four organs over prolonged culture periods. Recently, a two-organ platform was developed to investigate the cross-talk of human artificial liver microtissues and human neurospheres exposed to the common media flow over two weeks. The expression of lactate dehydrogenase and consumption of glucose proved the activity of liver cells, while neurospheres remained differentiated neurons over the prolonged twoweek culture. The incorporation of human brain ECs to this model in near future can be further used to study a biomimetic interaction of the brain with the liver to predict the safety and efficacy of substances in clinical studies (Fig. 7e) [307] . We recently developed the most complex multiorgan-on-chip platform, interconnecting the liver, heart and vasculature, along with integrated biophysical and biochemical biosensors for real-time monitoring the tissue microenvironment, measuring several important biomarkers related to the functionality or crosstalk of the tissues, and investigating the direct and side effects of drugs used for every organ (Fig. 7f) [308] . The next generation of multisensory integrated multiorgan platforms can provide real-time monitoring the interaction of the brain with other organs through the functional or dysfunctional brain-barriers including the BBB.
In overall, these microfluidic-based BBB-on-chip models, featuring the biomimetic compositions, architectures and functions of the human BBB, are expected to bridge the gap between the existing preclinical animal testing and clinical human body assessment. In particular, they are expected to provide exceptional advantages respect to the classical Transwell culture or co-culture systems such as 1) producing the 3D BBB construct in microscale similar to the brain capillary, respect to the 2D planar BBB in Transwell culture, 2) providing highly controlled shear stress to endothelium, 3) generating the microscale capillary network with biomimetic branching and flow conditions, useful to determine the microenvironmental conditions under which the BBB permeability is mimetically disrupted, 4) supplying in situ continual measuring of molecules and real-time assessment of the microenvironmental parameters, 5) enabling the longer-term coculture of constituting cells in a biomimetic environment compared to the short or medium-term culture of cells in planar models, 6) characterizing the interaction of immune cells or microbiome with the BBB under physiological conditions for further modeling several infectious diseases [311] , and 7) characterizing the dynamic responses of the engineered tissues to drug candidates over extended periods of time. The integration of biosensors to the BBB-on-chip models can further overcome the challenge of manual sample collection from small working volumes of the microfluidic systems that causes frequent system disturbance.
6.3. Other techniques and further applications of biomimetic BBB models 6.3.1. In silico techniques predicting the BBB permeability Despite significant advances in the development of biomimetic BBB models and promising approaches to use organ-on-chip platforms for drug testing, there is still a high cost of experiments for measuring the BBB permeability to screen candidates at first stages of the drug design. The advances in computational modeling can support the in vitro BBB models to reduce the cost of drug testing. In addition, a large number of target molecules are not studied yet in blood circulation; thereby they need to be carried in blood circulation through stable carriers. Nanotechnology has provided a variety of different nanocarriers that are stable in blood circulation, however they need to be permeable to the BBB.
Among different active and passive transportation methods [312, 313] , the computational models that are developed so far are primarily concerned with the passive diffusion through the lipid bilayer of the membrane of ECs [314] . To quantify the preference of compounds for their presence in the blood or brain media, the term logB-B = log (C brain / C blood ), known as blood-brain partition coefficient, has been defined as the most commonly used index of BBB permeability where C represents the equilibrium concentration of the compound. Experimentally, in vivo and in vitro methods have been used to measure logBB but both are still difficult and costly [315] [316] [317] [318] [319] [320] . Predicting the permeability of target molecules using computational techniques has been used as an alternative with promising results [314] . The designed BBB permeability models could be classified into two categories: models that predict the logBB value quantitatively and models that predict if a compound is permeable or not, so called as classifiers [321] . The quantitative predictors dominantly use the quantitative structure-activity relationship (QSAR) technique [314] and recently molecular dynamic (MD) simulation to predict logBB [322] . On the other hand, permeability classifiers use machine learning techniques, like neural networks and support vector machine (SVM) to examine whether a molecule, e.g. drug like molecules, is permeable [323] [324] [325] .
The QSAR models are essentially based on the assumption that all the information needed to predict logBB are encoded within the structure of the molecule of interest [326] . This method takes the advantage of currently available data on molecules with known logBB and subsequently models the correlation between logBB and molecular properties of the target molecules. Different molecular properties, known as molecular descriptors, such as molecular volume, solvent accessible surface area (SASA), polarity, hydrogen bond acidity and hydrogen bond basicity, polarizability, lipophilicity, solvation energy and octanol/water partition coefficient have been used in QSAR modeling [325, [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] .
The first quantitative model for the prediction of logBB was introduced by Levin by making a correlation between logBB, molecular weight (Mw) and octanol/water partition coefficient (logP) of molecules [324, 340] . Young et al. [316] reported a linear correlation between logBB and octanol-cyclohexane partition coefficient. More recently, other molecular descriptors such as hydrogen bond acidity and hydrogen bond basicity, molecular volume (Mv), refraction, and dipolarity/polarizability were used over a bigger training dataset, compared to previous studies [330, [337] [338] [339] . In addition, polar surface area (PSA) was introduced as another important molecular descriptor by Kelder et al. [341] and Clark. [342] . Following this line, a large number of other models have been developed during the last decade [325, [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] . As an example, Eq. 
where qp_num-amine, qp_EA, qp_PSA, No_AromaticRings, and ES_-Sum_sBr are the number of non-conjugated amine groups, PM3 calculated electron affinity, van der Waals surface area of polar nitrogen and oxygen atoms, number of aromatic rings, and atom-type E-state key, respectively. In general, qualitative models take the advantage of more available experimental data, while determining whether the BBB is permeable for a target molecule or not is easier than quantitative measurement of the molecule concentration on two sides of the BBB. Recently, Gupta et al. [343] trained a classifier with the accuracy as high as 98%, meanwhile they did not follow the traditional binary classification of permeability. Their classifier was able to classify a compound as high permeable (logBB ≥ 0.3), moderately permeable (0.3 > logBB ≥ −1.0), and low permeable (logBB < −1.0). Training of the model with a dataset is the basis of the QSAR technique, therefore both the quality and quantity of the training dataset are important. The first challenge for QSAR models is that a limited number of molecules with known logBB are available [315] [316] [317] [318] [319] [320] 344, 345] . In addition, besides the need to high quality data, for a specific compound, the model should be trained by data belonging to compounds with similar structures or at least close in their descriptor space, thereby the developed QSAR models cannot be generalized to the compounds outside the training dataset space [321, 322, 346] .
In addition to QSAR method, MD simulation has been recently employed to estimate logBB. MD method allows the simulation of different phenomena including diffusion [347] and permeability of cell membrane at the atomic level [348] . The combination of diffusion and free energy calculations using MD simulation was recently used to estimate the effective permeability of different compounds. They showed that the relative effective permeability is highly correlated to the experimental values of logBB [322] . The main advantage of using MD simulations is that for a target molecule, the only needed data is the structure of the molecule [322] . On the other hand, MD simulations are computationally expensive and for any new molecule, a new MD simulation should be set up. The systemic analysis is needed to explore the performance of different force fields in the prediction of logBB using MD simulation.
The prediction models of QSAR BBB permeability are traditionally built based on the assumption that a majority of data are obtained from the passive transpiration [349] . Recently, the role of active transportation has taken into account by considering a mixture of active and passive BBB permeability data as a training set [343, 350, 351] ; adding new descriptors like the high affinity P-gp substrate probability (HAPSP) and plasma protein binding ratio (PPBR) [324] ; or considering the passive and active data separately [352] . However, the size of dataset is limited and more data is needed to assess the accuracy and generality of the models [349] . In addition, the majority of mathematical models uses logBB data that can be affected by serum protein binding and active efflux, and the reported values may be different among different research groups [353] . On the other hand, the permeability surface area, reported as logPS, is a better measure for the permeability of compounds through the BBB [354] . However small datasets are available and thus there are a limited number of QSAR models trained using logPS [350, 355, 356] . Furthermore, besides the limited number and accuracy of available logBB data they are measured using different experimental techniques [349] . Altogether, building databases with an adequate number of compounds using consistent and accurate HT techniques is urgent for developing dependable and accurate models for virtual CNS drug screening. Here, one can use organon-chip technique to generate the passive/active specific data systematically with human cell lines.
Nanotechnology for effective drug delivery across BBB
Different types of nanostructures have been used as nanocarriers to deliver drugs across the BBB including liposomes [357] [358] [359] [360] [361] , polymeric nanoparticles [362] [363] [364] [365] , and dendrimers [366] [367] [368] . Polymer nanoparticles (NPs) are promising drug carriers that can cross the BBB with a great implication for the therapy of neurodegenerative diseases, given the fact that they can be modified to carry a variety of payload of drugs and genes. They are versatile in ligand conjugation, surface modification, and various fabrication methods [369] . Polymer NPs are attractive drug carriers due to their high stability in biological fluids compared to other NPs for the controlled and sustained drug release. Such properties reduce the side effects and unwanted diffusion of drugs [370] .
Various fabrication techniques are available to develop biodegradable NPs and modify the surface characteristics to cross the BBB. Biodegradable poly(n-butylcyanoacrylate) (PBCA) nanoparticles have been studied extensively showing the capability to cross the BBB [371, 372] . PBCA coated with polysorbate 80 has increased the concentration of Rivastigmine drug over 3.8 folds in the brain compared to the free drug [371, 372] . Jiang et al. [373] synthesized dendrigraft polyL-lysine conjugated with angiopep via polyethyleneglycol (DPA) as a gene delivery system for PD therapy. Encapsulated human glial cell line-derived neurotrophic factor (hGDNF) in DPA NPs were evaluated in Sprague-Dawley rats in a chronic PD model and presented an improved locomotor activity and an apparent recovery of dopaminergic neurons compared to other controls. Silica NPs (SiNPs), in particular, are of great interest for enhancing the passage of agents across the BBB due to their biocompatibility, relatively low cost, straightforward synthesis, facile surface modification, and partial urinary excretion [374] [375] [376] . Moreover, liposomes are effective carriers that can penetrate the BBB and subsequently target glioma cells. Dual-targeting doxorubincin (Dox) liposomes were produced by conjugating liposomes loaded with both folate (F) and transferrin (Tf), proved to be effective in penetrating the BBB and targeting brain tumors [377] .
The possibility of NPs uptake to the human CNS is still a major concern. While the majority of NPs drug delivery experiments were implemented by animal models [378] , in vitro BBB models have been also utilized to evaluate the permeability of NPs like PEGylated SiNPs across the BBB [379] . Although nanostructures have shown promising results on drug delivery through the BBB [380] , to the authors' best of knowledge, there is no mathematical model available for predicting nanostructures' permeability through the BBB. Like small molecules, there is a certain need for computational models that can assist us for the design of nanostructure-based drug delivery systems to characterize whether the system is BBB permeable and to select an appropriate carrier/drug formulation. However, without experimental data, building such a computational model is impossible. In addition, the complexity of such nanostructures is beyond simple small molecules and thereby the size of the needed dataset would be extremely large compared to the cost of computational models for small molecules. There is a room for the development of HT experimental techniques to generate biomimetic BBB models and produce accurate experimental data of the BBB permeability quickly.
Focused ultrasound mediated BBB disruption
In addition to the advances in nanotechnology to develop nanocarriers specific to the brain, other methods have been explored to overcome the BBB barrier. For instance, focused ultrasound (FUS) coupled with microbubbles allowed the non-invasive disruption of the BBB at specific regions for the delivery of drugs to their target destination in the brain [381] . This method enhances pharmacokinetical properties of drugs and allows large size drugs to enter into the brain [382] . The BBB disruption by FUS with microbubbles is reproducible and observable with MRI. Microbubbles are commercially available as ultrasound contrast agents ranging from 1-10 μm in size. They are made of lipid shells with a trapped gas, typically a perfluorocarbon [381] . The passage of brain-derived neurotropic factor (BDNF) cross the ultrasound-induced BBB opening has been studied by Babak et al. [383] . In a recent study, biodegradable PEG-coated polystyrene (PS) NPs were delivered to the brain parenchyma. The BBB was disrupted by FUS with microbubbles and were guided by MRI [384] . Further studies have shown that the disruption of the BBB generated by FUS is reversible [385] . FUS can be coupled with MRI targeting as well as diagnostic tools in therapeutic strategies. The primary potential of this technology is to target specific diseased areas of the brain and leave healthy parts untouched. Such a capability provides new insights in treating neurodegenerative disorders. In addition to drugs, the non-invasive method of MRI-guided focused ultrasound (MRIgFUS) was used for the delivery of stem cells from the blood by disrupting the BBB in specific brain regions [154, 386] . Immuno-histochemical analysis showed that GFP-positive cells, presented in the brain and neural stem cells, expressed common stem cell markers (nestin and polysialic acid). Mono-dispersed micro-bubbles with different sizes were injected intravenously in mice and sonicated using focused ultrasound [387] . The integration of miniaturized ultrasound systems to microfluidic-based BBB models is expected to provide a testing platform for assessing the efficacy of cell or drug transport through the BBB upon the local ultrasound manipulation of BBB permeability.
Conclusions
Novel technologies like microfluidics, tissue engineering and nanotechnology promise new opportunities for the development of biomimetic human BBB models. Such biomimetic models are expected to develop diseased models of the BBB; predict the permeability of molecules across the human BBB in both healthy and diseased states; assess the efficacy of drug transport across the BBB into the brain tissue; evaluate the clearance mechanisms of misfolded proteins from the brain; and determine the contribution of the BBB in the progression of neurodegenerative diseases or brain tumor upon the integration with biomimetic brain tissues. Furthermore, BBB-on-chip models can be linked to other organs to investigate the cross-talk of the brain with other tissues. Finally, computational models as the complementary strategy to the experimental BBB models can provide a predictive model for assessing the permeability of different molecules across the BBB. The future predictive models of the BBB are expected to take the advantages of new technologies for successful formulations of the BBB permeability and for the efficient delivery of low molecular weight drugs and biomacromolecules to the brain.
